Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM

Objective To analyze the effect of Risperidone ISM on social functioning and health-related quality of life (HR-QoL) in both short- and long-term treatment of patients with schizophrenia. Patients and Methods This analysis was based on data from both phases of the PRISMA-3 study, including 433 relapsed patients from the double-blind (DB) phase of the PRISMA-3 trial who were treated for 12-weeks with once-monthly (every 28 days) intramuscular Risperidone ISM 75 mg or 100 mg (n = 288), or placebo (n = 145), as well as 174 patients transitioning from the DB to an open-label 52-week extension (OLE) phase, plus 41 de novo patients treated on a stable maintenance dose of oral risperidone. The clinician-administered Personal and Social Performance (PSP) scale and the patient-reported 20-item Subjective Well-being under Neuroleptics scale (SWN-20) were used to measure social functioning and HR-QoL outcomes, respectively. Results Risperidone ISM significantly improved PSP total score from baseline to endpoint (Day 85) versus placebo in the DB phase with mean change total score (95% CI) of 10.7 (9; 12) compared to 4.8 (3; 7) for placebo (p < 0.0001). The statistically significant improvement was present from the first measurement time point (Day 29). SWN-20-measured HR-QoL increased on average in patients treated with Risperidone ISM in the DB phase. A significant improvement was also observed for PSP and SWN-20 scores from the OLE baseline to week 52 for patients transitioning from the DB phase. Stable de novo patients maintained similar PSP and SWN-20 scores during the whole OLE phase. Conclusion Risperidone ISM provided a rapid and sustained improvement in personal and social functioning, and HR-QOL without need of oral risperidone supplementation or loading doses. These findings, along with a fast onset of efficacy, could contribute to reinforcing the therapeutic alliance and possibly an earlier discharge. Moreover, patient functioning continued improving or was maintained with long-term treatment.

[1]  C. Álamo.  Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review , 2022, Advances in Therapy.

[2]  C. Correll,et al.  The antipsychotic paradox: Lessons regarding determinants of premature mortality , 2022, European Neuropsychopharmacology.

[3]  C. Correll,et al.  Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants , 2022, World psychiatry : official journal of the World Psychiatric Association.

[4]  I. Bitter,et al.  Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors , 2022, World psychiatry : official journal of the World Psychiatric Association.

[5]  C. Correll,et al.  Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics , 2022, Schizophrenia.

[6]  T. Furukawa,et al.  Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis , 2022, The Lancet.

[7]  L. Citrome,et al.  Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians , 2022, Neuropsychiatric disease and treatment.

[8]  C. Correll,et al.  Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study , 2021, Schizophrenia Research.

[9]  I. Gutierro,et al.  The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study , 2021, Drug design, development and therapy.

[10]  Bhing-Leet Tan,et al.  The Effect of Therapeutic Alliance on Attitudes Toward Psychiatric Medications in Schizophrenia , 2021, Journal of clinical psychopharmacology.

[11]  A. Tanskanen,et al.  Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study. , 2021, Schizophrenia bulletin.

[12]  T. Kishimoto,et al.  Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. , 2021, The lancet. Psychiatry.

[13]  Seung-hyun Kim,et al.  Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration. , 2021, The Journal of clinical psychiatry.

[14]  E. Balman,et al.  National Institute for Health and Care Excellence (NICE) , 2017, The Grants Register 2022.

[15]  C. Correll,et al.  Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation , 2020, npj Schizophrenia.

[16]  American Psychiatric Association.  The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia , 2020 .

[17]  B. Mancevski,et al.  Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia , 2019, Early intervention in psychiatry.

[18]  Andrea Cipriani,et al.  Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis , 2019, The Lancet.

[19]  R. Baker,et al.  The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies , 2019, Neuropsychiatric disease and treatment.

[20]  P. Weiden,et al.  Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study , 2019, Psychiatry Research.

[21]  M. Mimura,et al.  Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs , 2018, Acta psychiatrica Scandinavica.

[22]  P. Bozzatello,et al.  Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial , 2018, Clinical Drug Investigation.

[23]  James G. Scott,et al.  Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016 , 2018, Schizophrenia bulletin.

[24]  C. Hsieh,et al.  Responsiveness of the Personal and Social Performance scale in patients with schizophrenia , 2018, Psychiatry Research.

[25]  I. Gutierro,et al.  A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia , 2017, International clinical psychopharmacology.

[26]  J. Geddes,et al.  60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis and meta-regression of efficacy predictors , 2017 .

[27]  M. Morozova,et al.  Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1) , 2016, International clinical psychopharmacology.

[28]  J. Lauriello,et al.  The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. , 2016, The Journal of clinical psychiatry.

[29]  A. Vita,et al.  Schizophrenia , 2016, The Lancet.

[30]  A. Serrano-Blanco,et al.  Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia , 2016, Expert opinion on pharmacotherapy.

[31]  P. Rocca,et al.  Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life , 2016, Neuropsychiatric disease and treatment.

[32]  J. Kane,et al.  Effects of aripiprazole once-monthly on domains of personal and social performance: Results from 2 multicenter, randomized, double-blind studies , 2014, Schizophrenia Research.

[33]  P. Mortensen,et al.  Excess early mortality in schizophrenia. , 2014, Annual review of clinical psychology.

[34]  S. Potkin,et al.  Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia , 2013, BMC Psychiatry.

[35]  T. Kishimoto,et al.  Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. , 2013, Journal of clinical epidemiology.

[36]  A. Zwinderman,et al.  Psychometric evaluation of the Subjective Well-being Under Neuroleptic Treatment Scale (SWN) in patients with schizophrenia, their relatives and controls , 2013, Psychiatry Research.

[37]  J. G. Marques,et al.  The Portuguese version of the Personal and Social Performance Scale (PSP): reliability, validity, and relationship with cognitive measures in hospitalized and community schizophrenia patients , 2011, European Psychiatry.

[38]  J. Bobes,et al.  Validation of the Spanish Personal and Social Performance scale (PSP) in outpatients with stable and unstable schizophrenia. , 2011 .

[39]  S. Gopal,et al.  Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study , 2010, International clinical psychopharmacology.

[40]  C. Kozma,et al.  Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension , 2010, Annals of general psychiatry.

[41]  J. Lindenmayer,et al.  A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia , 2010, Journal of clinical psychopharmacology.

[42]  H. Nasrallah,et al.  Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention , 2010, Current medical research and opinion.

[43]  Philip D. Harvey,et al.  Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? , 2009, Schizophrenia bulletin.

[44]  D. Revicki,et al.  Psychometric properties of the Personal and Social Performance scale (PSP) among individuals with schizophrenia living in the community , 2008, Quality of Life Research.

[45]  M. Lambert,et al.  Rates and predictors of remission and recovery during 3 years in 392 never‐treated patients with schizophrenia , 2008, Acta psychiatrica Scandinavica.

[46]  Michael F. Green,et al.  Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. , 2007, Schizophrenia bulletin.

[47]  M. Swartz,et al.  Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. , 2006, The Journal of clinical psychiatry.

[48]  H. Rüdiger,et al.  Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs , 2001, Schizophrenia Research.

[49]  P. Morosini,et al.  Development, reliability and acceptability of a new version of the DSM‐IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning , 2000, Acta psychiatrica Scandinavica.

[50]  Chair,et al.  Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. , 1997, The American journal of psychiatry.

[51]  J. Rabe-Jabłońska,et al.  [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.

[52]  D. Mcniel,et al.  Violent behavior and length of psychiatric hospitalization. , 1989, Hospital & community psychiatry.

[53]  D. Cutler,et al.  Characteristics of state hospital patients who are hard to place. , 1988, Hospital & community psychiatry.

[54]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[55]  H. Akaike,et al.  Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .